Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Fractures: Bone Repair01:27

Fractures: Bone Repair

Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling and Repair01:31

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma.

Haematologica·2024
Same author

Osteocytes and Paget's Disease of Bone.

Current osteoporosis reports·2024
Same author

Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.

Haematologica·2023
Same author

The acid-sensing nociceptor TRPV1 controls breast cancer progression in bone via regulating HGF secretion from sensory neurons.

Research square·2023
Same author

Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation.

JCI insight·2023
Same author

Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction.

Neoplasia (New York, N.Y.)·2022
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

Ammonia in the crosshairs: microbial targets for metabolic dysfunction-associated steatohepatitis prevention.

The Journal of clinical investigation·2026
Same journal

Molecular mechanisms regulating cGAS/STING activation in health and disease.

The Journal of clinical investigation·2026
Same journal

Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma.

The Journal of clinical investigation·2026
Same journal

Nephrin autoimmunity: signal, noise, and a path to clarity.

The Journal of clinical investigation·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Bone building with bortezomib.

G David Roodman1

  • 1Office of Research and Development, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania 15240, USA.

The Journal of Clinical Investigation
|January 26, 2008
PubMed
Summary
This summary is machine-generated.

Bortezomib, a proteasome inhibitor, promotes mesenchymal stem/progenitor cells (MSCs) differentiation into bone-forming osteoblasts. This discovery offers new therapeutic strategies for bone loss and myeloma-related bone disease.

More Related Videos

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Related Experiment Videos

Last Updated: May 10, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Area of Science:

  • Bone Biology
  • Regenerative Medicine
  • Cancer Therapeutics

Background:

  • Multiple myeloma often leads to severe bone disease.
  • Current treatments may not fully address bone complications.
  • Mesenchymal stem/progenitor cells (MSCs) are crucial for bone repair.

Purpose of the Study:

  • To investigate the effect of bortezomib on MSC differentiation.
  • To evaluate bortezomib's potential in treating bone loss.
  • To explore therapeutic strategies for myeloma-associated bone disease.

Main Methods:

  • Treatment of mice with bortezomib.
  • Subcutaneous implantation of MSCs in mice.
  • Assessment of bone formation and MSC differentiation.

Main Results:

  • Bortezomib induced differentiation of MSCs into osteoblasts.
  • This differentiation resulted in new bone formation.
  • The effect was observed in models of bone loss and MSC implantation.

Conclusions:

  • Bortezomib promotes osteoblast differentiation from MSCs, leading to bone formation.
  • Targeting endogenous MSCs is a viable strategy for tissue repair.
  • Combination therapies inhibiting bone resorption and promoting formation may benefit myeloma patients.